Noninvasive Detection of Programmed Cell Loss with $^{99m}$Tc-Labeled Annexin A5 in Heart Failure

Bas L.J.H. Kietelsen1, Chris P.M. Reutelingsperger2, Hendrikus H. Boersma3,4, Guido A.K. Heidendal4, Ing Han Liem5, Harry J.G.M. Crijns1, Jagat Narula6, and Leo Hofstra1

1Department of Cardiology, University Hospital of Maastricht, Maastricht, The Netherlands; 2Department of Biochemistry, University of Maastricht, Maastricht, The Netherlands; 3Department of Clinical Pharmacy, University Hospital of Maastricht, Maastricht, The Netherlands; 4Department of Nuclear Medicine, University Hospital of Maastricht, Maastricht, The Netherlands; 5Department of Nuclear Medicine, Maxima Medical Center, Veldhoven, The Netherlands; and 6Division of Cardiology, University of California, Irvine College of Medicine, Irvine, California

Apoptosis, or programmed cell death (PCD), contributes to the decline in ventricular function in heart failure. Because apoptosis comprises a programmed cascade of events, it is potentially reversible, and timely intervention should delay the development of cardiomyopathy. $^{99m}$Tc-Labeled annexin A5 has successfully been used for the noninvasive detection of PCD in myocardial infarction and heart transplant rejection. The present study evaluated the role of annexin A5 imaging for detection of PCD in heart failure patients. Methods: Annexin A5 imaging was performed on 9 consecutive heart failure patients with advanced nonischemic cardiomyopathy (dilated, n = 8; hypertrophic, n = 1) and in 2 relatives having the same genetic background as the hypertrophic cardiomyopathy patient but no heart failure. Results: Four of the patients with dilated cardiomyopathy and the 1 with hypertrophic cardiomyopathy and heart failure showed focal, multifocal, or global left ventricular uptake of annexin A5. No uptake was visualized in the remaining 4 patients or in the 2 controls. All cases showing annexin A5 uptake within the left ventricle experienced significant reduction in left ventricular function or functional class. In cases with no annexin A5 uptake, left ventricular function and clinical status remained stable. Conclusion: These data indicate the feasibility of noninvasive PCD detection with annexin imaging in heart failure patients. Annexin A5 uptake is associated with deterioration in left ventricular function, and this association may lend itself to the development of novel management strategies.

Key Words: apoptosis; heart failure; annexin A5

DOI: 10.2967/jnumed.106.039453

Heart failure is becoming the most important cardiovascular health problem (1), and strategies that allow recognition of potentially reversible myocardial damage may have a significant clinical impact. Heart failure is characterized by inexorable deterioration in ventricular function (2,3). Apoptosis, or programmed cell death (PCD), of cardiomyocytes has been proposed as an important process that mediates the slow, ongoing loss of heart muscle cells and ventricular dysfunction (4–7). Antiapoptotic intervention is known to delay and prevent the occurrence or minimize the severity of heart failure in animal models (8,9). Because apoptosis is genetically programmed and can be modified, it is important to develop techniques for noninvasive detection of PCD in heart failure (10).

Activation of caspase 3, the hallmark of PCD, leads to alterations in the assortment of phospholipids in the sarcoplasmic lipid bilayer, resulting in externalization of phosphatidyl serine (PS) to the outer surface of the cell membrane (11,12). PS externalization has successfully been detected noninvasively by radionuclide imaging with $^{99m}$Tc-labeled annexin A5 (13,14). The clinical feasibility of imaging with annexin A5 has been demonstrated in patients presenting with acute myocardial infarction (13), cardiac allograft rejection (15), or malignant intramyocardial masses (14). We studied the feasibility of annexin A5 imaging for the detection of PCD in a small group of patients with advanced heart failure.

MATERIALS AND METHODS

Patients

Annexin A5 imaging was performed on 9 consecutive patients admitted with nonischemic cardiomyopathy and advanced heart failure. Their ages ranged from 35 to 64 y, and 6 of the 9 patients were male. New York Heart Association class II, III, and IV symptoms were reported for 1, 5, and 3 patients, respectively. Eight patients had idiopathic dilated cardiomyopathy (patients 1–8), and failure had recently worsened in 4 patients (patients 3, 6, 7, and 8), with a reduction by at least 1 New York Heart Association functional class during the past 3 mo. In the remaining patient (patient 9) heart failure had developed secondary to familial hypertrophic cardiomyopathy caused by a mutation in the myosin gene at locus 14q11–q12. Two relatives of patient 9 (aged 33 and 36 y, both women) with the same myosin gene mutation, a hypertrophic echocardiographic phenotype, and normal left ventricular ejection fraction (LVEF)
also underwent annexin A5 imaging as hypertrophic but non-failing controls. Patient characteristics are summarized in Table 1.

Echocardiography was performed on all patients at the time of imaging. LVEF was assessed by 2-dimensional echocardiography. The inner myocardial wall of the left ventricle was traced in both the end-diastolic phase and the end-systolic phase. Using modified Simpson's analysis (16), we assessed LVEF. Patients were followed up routinely in the cardiology department of our hospital as outpatients. LVEF was reassessed by echocardiography after 1 y in all patients except the hypertrophic controls.

Annexin A5 Labeling and SPECT Study Protocol

Human recombinant annexin A5 (Theseus Imaging Corp.) was labeled with 1 GBq of $^{99m}$Tc for imaging. Six hours before imaging, 0.25 mg of human recombinant $^{99m}$Tc-annexin A5 was administered intravenously. In addition, 32–48 MBq of $^{201}$Tl were administered 30 min before imaging. All scintigraphic studies were performed using a MultiSPECT2 dual-head γ-camera (Siemens). A dual-isotope imaging protocol was used to acquire $^{99m}$Tc and $^{201}$Tl data simultaneously. For $^{99m}$Tc data, an energy peak of 140 keV with a window of 15% was used. $^{201}$Tl data were acquired using peaks of 166 keV and 70 keV and windows of 15% and 20%, respectively. We used a $64 \times 64$ matrix and 64 angled views, counting each angle for 60 s. Studies were reconstructed with a backprojection method. Standard views of the left ventricle were constructed using the $^{201}$Tl dataset. Limits and orientation of the left ventricle were transferred onto the $^{99m}$Tc-annexin dataset. Because of simultaneous acquisition of these data, we were able to precisely localize myocardial uptake of $^{99m}$Tc-annexin A5. Radiation exposure was calculated to between 3.4 and 4.5 mSv. Two readers, unaware of the clinical information, assessed the SPECT data independently. The study complied with the Declaration of Helsinki and was approved by the institutional review committee of the University Hospital of Maastricht. All subjects gave written informed consent.

**RESULTS**

Patients 1–9 had advanced heart failure due to non-ischemic cardiomyopathy. Before a patient was entered into the study, the absence of coronary artery disease was confirmed by coronary angiography. Standard 2-dimensional echocardiography did not show regional wall motion abnormalities. LVEF ranged from 15% to 31% at the time of annexin A5 imaging. LVEF in the 2 control subjects was 52% and 73%, respectively.

Of the 9 congestive heart failure patients, 5 showed annexin A5 uptake in the left ventricular myocardium; no uptake was observed in the right ventricle. The uptake was focal in 1 patient (patient 6), multifocal in 2 patients (patients 3 and 7) (Fig. 1A), and diffuse in 1 patient (patient 9) (Fig. 1B). Myocardial perfusion was essentially normal in these patients, and the areas of annexin A5 uptake did not correspond to a single coronary territory as often observed in myocardial infarction. All 4 dilated cardiomyopathy patients with annexin A5 uptake had experienced a significant worsening or the onset of heart failure in the past 3 mo. Similarly, the patient with the myosin gene mutation demonstrated positive, diffuse uptake and had experienced a substantial decrease in LVEF in the past 6 mo.

The remaining 4 heart failure patients did not show uptake of the radiotracer (Fig. 1C). These patients had poor left ventricular function (LVEF, 25%–31%) but had no recent evidence of worsening of heart failure. The 2 family members of the hypertrophic cardiomyopathy patient, with the myosin gene mutation and echocardiographic evidence of left ventricular hypertrophy and preserved LVEF, did not show radiolabeled annexin uptake (Fig. 1D).

During a follow-up of 1 y, the 4 patients with annexin A5 uptake showed, on average, a decline in LVEF. On the other hand, in the annexin A5–negative patients, LVEF remained stable or increased somewhat after 1 y of follow-up. Figure 2 depicts the change in ejection fraction, subtracting LVEF at the time of imaging from LVEF 1 y after imaging. Student $t$ testing for paired samples showed a significant difference

**TABLE 1**

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Diagnosis</th>
<th>NYHA functional class</th>
<th>LVEF study (%)</th>
<th>Outcome of annexin A5 study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Before study</td>
<td>At time of study</td>
<td>At time of annexin imaging</td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>63</td>
<td>DCM</td>
<td>III</td>
<td>III</td>
<td>25</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>35</td>
<td>DCM</td>
<td>II</td>
<td>II</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>39</td>
<td>DCM</td>
<td>I</td>
<td>III</td>
<td>45</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>52</td>
<td>DCM</td>
<td>III</td>
<td>III</td>
<td>31</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>50</td>
<td>DCM</td>
<td>III</td>
<td>III</td>
<td>17</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>58</td>
<td>DCM</td>
<td>IV</td>
<td>IV</td>
<td>48</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>64</td>
<td>DCM</td>
<td>III</td>
<td>IV</td>
<td>21</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>41</td>
<td>DCM</td>
<td>III</td>
<td>IV</td>
<td>20</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>33</td>
<td>HCM</td>
<td>II</td>
<td>IV</td>
<td>26</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>36</td>
<td>HCM</td>
<td>I</td>
<td>I</td>
<td>52</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>37</td>
<td>HCM</td>
<td>I</td>
<td>I</td>
<td>73</td>
</tr>
</tbody>
</table>

NYHA = New York Heart Association; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; NA = not applicable.
between patients positive and negative for annexin A5 uptake ($P = 0.038$).

**DISCUSSION**

**Apoptosis in Heart Failure**

PCD contributes to slow, ongoing myocardial dysfunction in heart failure (17). Cytokinenia and ischemic/oxidative stress have been shown to lead to a release of cytochrome c from the mitochondria into the cytoplasmic compartment and to the activation of caspase 3 (18). Active caspase 3 cleaves contractile proteins and activates DNA fragmentation enzymes. The loss of cytochrome c (hence the loss of the energy production mechanism in mitochondria) and the fragmentation of contractile proteins contribute to a decline in left ventricular function. Activation of caspase 3 also results in scrambling of cell membrane phospholipids, thereby expressing PS (target for annexin imaging). However, the simultaneous activation of various antiapoptotic factors in the failing myocardium inhibits caspase-mediated activation of
Noninvasive Imaging of PCD

For patients with higher amounts of antiapoptotic factors (hence more PS expression and annexin A5 positivity) would be better candidates for exogenous antiapoptotic therapy. These data should be interpreted carefully because of the small number of patients in the study. Further prospective trials including larger numbers of dilated cardiomyopathy patients with sequential scans and functional follow-ups may clarify the current observations. Because $^{201}$Tl $\gamma$-photons also have an energy peak at 166 keV, there may be some downscatter into the 140-keV window of $^{99m}$Tc. However, this downscatter was not observed in the family members of the hypertrophic cardiomyopathy patient (Fig. 1D). In addition, we did not observe downscatter in patients included in other studies (unpublished data, November 2006). Furthermore, annexin A5 uptake is focal in most patients, whereas downscatter from $^{201}$Tl should appear throughout the left ventricle. Endomyocardial biopsies were not performed in the present study. Because biopsies are not likely to influence management strategy, the ethical committee did not allow biopsies for research purposes and merely for comparison with the results of annexin A5 scans. In addition, serial annexin A5 scans were not allowed. The lack of endomyocardial

Limitations of Study

These data should be interpreted carefully because of the small number of patients in the study. Further prospective trials including larger numbers of dilated cardiomyopathy patients with sequential scans and functional follow-ups may clarify the current observations. Because $^{201}$Tl $\gamma$-photons also have an energy peak at 166 keV, there may be some downscatter into the 140-keV window of $^{99m}$Tc. However, this downscatter was not observed in the family members of the hypertrophic cardiomyopathy patient (Fig. 1D). In addition, we did not observe downscatter in patients included in other studies (unpublished data, November 2006). Furthermore, annexin A5 uptake is focal in most patients, whereas downscatter from $^{201}$Tl should appear throughout the left ventricle. Endomyocardial biopsies were not performed in the present study. Because biopsies are not likely to influence management strategy, the ethical committee did not allow biopsies for research purposes and merely for comparison with the results of annexin A5 scans. In addition, serial annexin A5 scans were not allowed. The lack of endomyocardial

Other Noninvasive Imaging Studies of Heart Failure

Previous imaging studies for detection of cell death in heart failure were performed using antimyosin antibodies and showed evidence of myocardial necrosis in such patients (23,26). Patients with antimyosin uptake were shown to have a high likelihood of myocarditis or evidence of noninflammatory myocyte degeneration in their endomyocardial biopsy samples. Patients with scans positive for antimyosin showed functional improvement over time, in contrast to those with scans negative for antimyosin. The functional improvement in antimyosin-positive patients appears to be counterintuitive. It was proposed that the antimyosin positivity in dilated cardiomyopathy represented merely the extent of acute myocardial insult and that the accompanying irreversibly damaged, antimyosin-negative myocytes were responsible for functional resolution (23). In contrast, in annexin A5 imaging, annexin-positive patients continue to show a decrease in left ventricular function, and annexin-negative patients show improved left ventricular function. We can only surmise that the antimyosin-positive cells were an indirect marker of reversible cells, whereas the annexin-positive cells represented the true state of balance of proapoptotic and antiapoptotic factors in the cardiomyocytes and should be more predictive of prognosis. It is apparent that the cells with lower amounts of antiapoptotic factors (hence more PS expression and annexin A5 positivity) would be better candidates for exogenous antiapoptotic therapy. These findings have been translated into Figure 3.

Limitations of Study

These data should be interpreted carefully because of the small number of patients in the study. Further prospective trials including larger numbers of dilated cardiomyopathy patients with sequential scans and functional follow-ups may clarify the current observations. Because $^{201}$Tl $\gamma$-photons also have an energy peak at 166 keV, there may be some downscatter into the 140-keV window of $^{99m}$Tc. However, this downscatter was not observed in the family members of the hypertrophic cardiomyopathy patient (Fig. 1D). In addition, we did not observe downscatter in patients included in other studies (unpublished data, November 2006). Furthermore, annexin A5 uptake is focal in most patients, whereas downscatter from $^{201}$Tl should appear throughout the left ventricle. Endomyocardial biopsies were not performed in the present study. Because biopsies are not likely to influence management strategy, the ethical committee did not allow biopsies for research purposes and merely for comparison with the results of annexin A5 scans. In addition, serial annexin A5 scans were not allowed. The lack of endomyocardial
biopsies precludes the diagnosis of myocarditis in scan-positive patients. Because none of the scan-positive patients showed an improvement in LVEF, the likelihood of myocarditis in those cases is low.

CONCLUSION

This proof-of-principle study suggests that annexin A5 imaging may identify accelerated myocardial cell loss in nonischemic dilated cardiomyopathy patients with a recent worsening of heart failure. Such a strategy may offer a new possibility for studying interventions to minimize the progression of myocardial dysfunction.

REFERENCES


---

**Erratum**

In the article “Integrin Receptor Imaging of Breast Cancer: A Proof-of-Concept Study to Evaluate 99mTc-NC100692,” by Bach-Gansmo et al. (*J Nucl Med.* 2006;47:1434–1439), the legends for Figures 4 and 5 were inadvertently transposed. The authors regret the error.